Viking Therapeutics, Inc. (VKTX) Q2 2019 Earnings Results

Viking Therapeutics Misses on EPS, Stock Down 1.56%

Viking Therapeutics reported a loss per share of $0.11, but did not provide revenue figures. The stock fell 1.56% following the earnings report, reflecting investor uncertainty about the company's future performance and lack of guidance. The management's cautious tone suggests they are aware of the challenges ahead but remain focused on their development pipeline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.11	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management remains focused on advancing their clinical programs. They emphasized the need for patience as they navigate the development landscape.

Management highlighted ongoing development efforts and the importance of upcoming clinical trials.

They expressed confidence in their pipeline but acknowledged the challenges ahead.

Viking Therapeutics Misses on EPS, Stock Down 1.56%

Key numbers

Management commentary

Viking Therapeutics, Inc.

More earnings this week

Viking Therapeutics Misses on EPS, Stock Down 1.56%

Key numbers

Management commentary